Oral administration of a liquid formulation of bcx7353 rapidly provides sustained concentrations and kallikrein inhibition

BCX7353 is an investigational oral kallikrein inhibitor in Phase 3 studies for prevention of HAE attacks. A capsule formulation of BCX7353 is rapidly absorbed  and exhibits a long half-life, which also may permit effective treatment of acute attacks in HAE patients. A Phase I study in HAE patients was conducted to determine whether a liquid formulation of BCX7353 may optimize on these attributes as an attack treatment.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: P153 Source Type: research